Obstetric Interventions Beneficial to Prematurely Delivering Newborn Babies: Antenatal Corticostetroids, Progesterone, Magnesium Sulfate

Clinics in Perinatology

Volumn 39, Issue 1, 2012, Pages 33-45

  Garite, Thomas J ^a,b,c   Combs, C Andrew ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PEDIATRIX MEDICAL GROUP   (United States)

^c American Journal of Obstetrics and Gynecology   (United States)

^d Obstetrix Medical Group   (United States)

Author keywords

Antenatal corticosteroids; Magnesium sulfate; Prematurity; Progesterone

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; BETAMETHASONE; CORTICOSTEROID; DEXAMETHASONE; HYDROXYPROGESTERONE CAPROATE; MAGNESIUM SULFATE; PLACEBO; PROGESTERONE; PROTIRELIN;

CEREBRAL PALSY; DIET THERAPY; DRUG EFFICACY; GESTATION PERIOD; HUMAN; LOW DRUG DOSE; LUNG COMPLIANCE; MATERNAL CARE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NEWBORN MORBIDITY; NONHUMAN; OBSTETRIC PROCEDURE; OPTIMAL DRUG DOSE; PREECLAMPSIA; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEATED DRUG DOSE; RETREATMENT; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; RISK REDUCTION; SECOND TRIMESTER PREGNANCY; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; VAGINITIS;

ADRENAL CORTEX HORMONES; CEREBRAL PALSY; FEMALE; FETAL DEATH; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENTS; PREGNANCY; PREMATURE BIRTH; PRENATAL CARE; PROGESTERONE;

EID: 84857070926     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2011.12.012     Document Type: Review

References (62)

1. Prematurity: March of dimes web site. Available at: Accessed December 20, 2011. http://www.marchofdimes.com/mission/prematurity_indepth.html.
2. Liggins G.C., Howie R.N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972, 50:515-525.
3. Crowley P. Antenatal corticosteroid therapy: a metaanalysis of the randomized trials 1972-1994. Am J Obstet Gynecol 1995, 173:322-335.
4. Leviton L.L., Baker S., Hassol A., et al. An exploration of opinion and practice patterns affecting low use of antenatal corticosteroids. Am J Obstet Gynecol 1995, 173:312-316.
5. NIH Consensus Conference Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. JAMA 1995, 273:413-418.
6. Doran T.A., Swyer P., MacMurray B., et al. Results of a double-blind controlled study on the use of betamethasone in the prevention of respiratory distress syndrome. Am J Obstet Gynecol 1980, 136:313-320.
7. Shutte M.F., Treffers P.E., Koppe J.G., et al. The influence of betamethasone and orciprenaline on the incidence of respiratory distress syndrome in the newborn after premature labor. Br J Obstet Gynaecol 1980, 87:127-131.
8. Terramo K., Hallman M., Raivio K.O. Maternal glucocorticoid in unplanned premature labor. Pediatr Res 1980, 14:326-329.
9. Collaborative Group on Antenatal Steroid Therapy. Effect of antenatal steroid administration on prevention of respiratory distress syndrome. Am J Obstet Gynecol 1981, 141:276-287.
10. Morales W.J., Diebel N.D., Lazar A.J., et al. The effect of antenatal dexamethasone of the prevention of respiratory distress syndrome in preterm gestation with premature of membranes. Am J Obstet Gynecol 1986, 154:591-595.
11. Garite T.J., Rumney P.J., Briggs G.G., et al. A randomized placebo controlled trial of betamethasone for the prevention of respiratory distress syndrome at 24-18 weeks gestation. Am J Obstet Gynecol 1992, 166:646-651.
12. Planer B.C., Ballard R.A., Ballard P. Antenatal corticosteroid use in preterm labor in the USA. Pediatr Res 1996, 39:110.
13. Antenatal corticosteroids revisited: repeat courses. NIH Consens Statement 2000, 17:1-18.
14. Banks B.A., Cnaan A., Morgan M.A., et al. Multiple courses of antenatal corticosteroids and outcome of premature neonates. Am J Obstet Gynecol 1999, 181:709-717.
15. French N.P., Hagan R., Evans S.F., et al. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 1999, 180:114-121.
16. Guinn D.A., Atkinson M.W., Sullivan L., et al. Single vs. weekly courses of antenatal for corticosteroids for women at risk of preterm delivery: a randomized controlled trial. JAMA 2001, 286:1581-1587.
17. Wapner R.J., Sorokin Y., Thom E.A., National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network, et al. Single vs. weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. Am J Obstet Gynecol 2006, 195:633-642.
18. Crowther C.A., Haslam R.R., Hiller J.E., Australian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) Study Group, et al. Neonatal respiratory distress after repeat exposure to antenatal corticosteroids: a randomised controlled trail. Lancet 2006, 367:1913-1919.
19. Murphy K.E., Hannah M.E., Willan A.R., et al. MACS Collaborative Group Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet 2008, 372:2143-2251.
20. Wapner R.J., Sorokin Y., Mele L., et al. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med 2007, 357:1190-1198.
21. Crowther C.A., Doyle L.W., Haslam R.R., et al. Outcomes at 2 years after repeat doses of antenatal corticosteroids. N Engl J Med 2007, 357:1179-1189.
22. Vermillion S.T., Bland M.L., Soper D.E. Effectiveness of a rescue dose of antenatal betamethasone after an initial single dose. Am J Obstet Gynecol 2001, 185:1086-1089.
23. Mercer B. Randomized controlled trial of weekly vs. rescue antenatal corticosteroids [abstract]. Presented at the Annual Meeting of the Society of Maternal Fetal Medicine. Reno, February 1-3, 2001.
24. Garite T.J., Kurtzman J., Maurel K., Obstetrix Collaborative Research Network, et al. Impact of a rescue course of antenatal corticosteroids: a multicenter randomized placebo-controlled trial. Am J Obstet Gynecol 2009, 200:248.e1-248.e9.
25. McEvoy C., Schilling D., Peters D., et al. Respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial. Am J Obstet Gynecol 2010, 202:544.
26. American Congress of Obstetricians and Gynecologists. Antenatal corticosteroid therapy for fetal maturation. ACOG Committee Opinion #475, February, 2011.
27. Vermillion S.T., Soper D.E., Chasedunn-Roark J. Neonatal sepsis after betamethasone to patients with preterm premature rupture of membranes. Am J Obstet Gynecol 1999, 181:320-327.
28. Lee M., Davies J., Guinn D., et al. Single vs. weekly course of antenatal corticosteroids in preterm premature rupture of membranes. Obstet Gynecol 2004, 103:274-281.
29. Nelson K.B., Grether J.K. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?. Pediatrics 1995, 95:263-269.
30. Conde-Agudelo A., Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol 2009, 200:595-609.
31. Crowther C.A., Hiller J.E., Doyle L.W., et al. Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003, 290:2669.
32. Marret S., Marpeau L., Zupan-Simunek V., et al. PREMAG trial group Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. Br J Obstet Gynaecol 2007, 114:310-318.
33. Rouse D.J., Hirtz D.G., Thom E., et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008, 359:895-905.
34. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia: outcome for children at 18 months. Br J Obstet Gynaecol 2007, 114:289-299. Magpie Trial Follow-Up Study Collaborative Group.
35. Burd I., Breen K., Friedman A., et al. Magnesium sulfate reduces inflammation-associated brain injury in fetal mice. Am J Obstet Gynecol 2010, 202:292.e1-292.e9.
36. American Congress of Obstetricians and Gynecologists. Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection. ACOG Committee Opinion #455, March 2010.
37. Rouse D. Magnesium sulfate for the prevention of cerebral palsy. Am J Obstet Gynecol 2009, 200:610-612.
38. Romero R. Prevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment. Ultrasound Obstet Gynecol 2007, 30:675-686.
39. Csapo A.I. The "see-saw" theory of parturition. The fetus and birth 1977, 159. Elsevier/Excerpta Medica, Amsterdam. J. Knight, M. O'Connor (Eds.).
40. Johnson J.W., Austin K.L., Jones G.S., et al. Efficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975, 293:675-680.
41. Keirse M.J. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990, 97:149-154.
42. Meis P.J., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003, 348:2379-2385.
43. Da Fonseca E.B., Bittar R.E., Carvalho M.H., et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003, 188:2419-2424.
44. O'Brien J.M., Adair C.D., Lewis D.F., et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007, 30:687-696.
45. Hartikainen-Sorri A.L., Kauppila A., Tuimala R. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980, 56:692-695.
46. Rouse D.J., Caritis S.N., Peaceman A.M., et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007, 357:454-461.
47. Briery C.M., Veillon E.W., Klauser C.K., et al. Progesterone does not prevent preterm births in women with twins. South Med J 2009, 102:900-904.
48. Combs C.A., Garite T., Maurel K., et al. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol 2011, 204. e1-8.
49. Lim A.C., Schuit E., Bloemenkamp K., et al. 17alpha-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. Obstet Gynecol 2011, 118:513-520.
50. Rode L., Klein K., Nicolaides K.H., et al. Prevention of preterm delivery in twin gestations (PREDICT): a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 2011, 38:272-280.
51. Cetingtoz E., Cam C., Sakalli M., et al. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. Arch Gynecol Obstet 2011, 283:423-429.
52. Norman J.E., Mackenzie F., Owen P., et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): a randomized, double-blind, placebo-controlled study and meat-analysis. Lancet 2009, 372:2034-2240.
53. Caritis S.N., Rouse D.J., Peaceman A.M., et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trail. Obstet Gynecol 2009, 113(2 Pt 1):285-292.
54. Combs C.A., Garite T., Maurel K., et al. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a doubleblind, randomized clinical trial. Am J Obstet Gynecol 2010, 203:248.e1-248.e9.
55. Iams J.D., Goldenberg R.L., Meis P.J., et al. NICHD MFM Network. The length of the cervix and the risk of spontaneous premature delivery. N Engl J Med 1996, 334:567-572.
56. DeFranco E.A., O'Brien J.M., Adair C.D., et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007, 30:697-705.
57. Fonseca E.B., Celik E., Parra M., et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007, 357:462-469.
58. Hassan S.S., Romero R., Vidyadhari D., et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a milticenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011, 38(1):18-31.
59. Nothen A.T., Norman G.S., Anderson K., et al. follow up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007, 110:865-872.
60. Klein K., Rode L., Nicolaides K.H., et al. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol 2011, 38(3):281-287.
61. American Congress of Obstericians and Gynecologists. Use of Progesterone to Reduce Preterm Birth. ACOG Committee Opinion #419, October, 2008.
62. Cahill A.G., Odibo A.O., Caughey A.B., et al. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol 2010, 202. 548, e1-8.